Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Revenue
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
ISRG 
Intuitive Surgical Inc (ISRG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/01/2025: ISRG (5-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Outstanding Performance
These Stocks/ETFs, based on Upturn Advisory, have historically outperformed the market, making them a top-tier choice for investors.
AI Based Fundamental Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Analysis of Past Performance
Type Stock | Historic Profit 84.07% | Avg. Invested days 75 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  4.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 04/01/2025 |
Key Highlights
Company Size Large-Cap Stock | Market Capitalization 177.83B USD | Price to earnings Ratio 77.07 | 1Y Target Price 624.78 |
Price to earnings Ratio 77.07 | 1Y Target Price 624.78 | ||
Volume (30-day avg) 2357934 | Beta 1.43 | 52 Weeks Range 364.17 - 616.00 | Updated Date 04/1/2025 |
52 Weeks Range 364.17 - 616.00 | Updated Date 04/1/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) 6.44 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Products
Product revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin 27.81% | Operating Margin (TTM) 31.33% |
Management Effectiveness
Return on Assets (TTM) 8.67% | Return on Equity (TTM) 15.62% |
Valuation
Trailing PE 77.07 | Forward PE 62.5 | Enterprise Value 173819864076 | Price to Sales(TTM) 21.29 |
Enterprise Value 173819864076 | Price to Sales(TTM) 21.29 | ||
Enterprise Value to Revenue 20.81 | Enterprise Value to EBITDA 61.84 | Shares Outstanding 358275008 | Shares Floating 354517022 |
Shares Outstanding 358275008 | Shares Floating 354517022 | ||
Percent Insiders 0.52 | Percent Institutions 89.39 |
Analyst Ratings
Rating 4.06 | Target Price 566.97 | Buy 9 | Strong Buy 14 |
Buy 9 | Strong Buy 14 | ||
Hold 9 | Sell - | Strong Sell 1 | |
Strong Sell 1 |
Upturn AI SWOT
Intuitive Surgical Inc
Company Overview
History and Background
Intuitive Surgical Inc. was founded in 1995 and is headquartered in Sunnyvale, California. Initially focused on robotic-assisted surgery, the company's flagship product, the da Vinci Surgical System, revolutionized minimally invasive procedures. Over time, it expanded its product portfolio and global reach, becoming a leader in surgical robotics.
Core Business Areas
- Surgical Systems: Designs, manufactures, and markets da Vinci surgical systems and related instruments and accessories. This segment contributes the largest portion of revenue.
- Instruments and Accessories: Sells instruments, endoscopes, and accessories used with the da Vinci Surgical System. This is a recurring revenue stream tied to procedure volume.
- Services: Provides services, including installation, training, maintenance, and repair services for da Vinci systems.
Leadership and Structure
Intuitive Surgical is led by CEO Gary S. Guthart. The organizational structure is hierarchical, with various departments responsible for research and development, manufacturing, sales and marketing, and customer support.
Top Products and Market Share
Key Offerings
- da Vinci Surgical System: The flagship robotic-assisted surgical system. It is estimated that Intuitive Surgical holds over 70% market share in the surgical robotics space. Competitors include Stryker's Mako system and Medtronic's Hugo system. Revenue from da Vinci systems constitutes a significant portion of the company's total revenue. Number of da Vinci systems installed worldwide is in excess of 7,500 as of 2023.
- Ion Endoluminal System: A robotic-assisted platform for minimally invasive biopsy in the lung. Competitors include Auris Health (now Johnson & Johnson) and Medtronic. The lung biopsy market is large, but Intuitive Surgical is relatively new to this market.
Market Dynamics
Industry Overview
The surgical robotics market is experiencing rapid growth due to factors like the increasing adoption of minimally invasive surgery, technological advancements, and aging populations. The market is highly competitive and innovation-driven.
Positioning
Intuitive Surgical is a dominant player in the surgical robotics market, holding a strong market share with the da Vinci Surgical System. The company's competitive advantages include its established brand, extensive clinical data supporting the da Vinci system, and a large installed base of systems.
Total Addressable Market (TAM)
Estimates for the total addressable market for surgical robotics range from $50 billion to $80 billion. Intuitive Surgical is well-positioned to capture a significant portion of this TAM due to its established market presence and technological leadership.
Upturn SWOT Analysis
Strengths
- Strong brand recognition
- Large installed base of da Vinci systems
- Extensive clinical data supporting da Vinci procedures
- Recurring revenue from instruments, accessories, and services
- High barriers to entry in the surgical robotics market
- Global presence.
Weaknesses
- High cost of da Vinci systems
- Dependence on da Vinci platform
- Potential for increased competition
- Limited reimbursement for some procedures.
- Training requirements for surgeons
Opportunities
- Expanding the use of surgical robotics into new surgical specialties
- Developing new robotic platforms for different applications
- Growing the installed base in emerging markets
- Acquiring complementary technologies and businesses
- Integrating AI and data analytics into surgical platforms.
Threats
- Increasing competition from established medical device companies and new entrants
- Technological obsolescence
- Changes in healthcare regulations and reimbursement policies
- Product liability lawsuits
- Economic downturns affecting hospital capital spending.
Competitors and Market Share
Key Competitors
- STRY (Stryker)
- MDT (Medtronic)
- JNJ (Johnson & Johnson)
Competitive Landscape
Intuitive Surgical benefits from a first-mover advantage and a large installed base, leading to strong brand recognition and surgeon familiarity. Competitors are trying to catch up by offering more cost effective solutions and targeting smaller segments of the surgical market. Intuitive has a large, validated ecosystem, but it can be slow to adapt and change. New, nimbler companies may innovate with disruptive technology.
Major Acquisitions
Orpheus Medical
- Year: 2018
- Acquisition Price (USD millions): 300
- Strategic Rationale: Orpheus Medical's technology provides a platform for capturing and managing surgical video and images. This strategic acquisition would expand the company's technology portfolio for collecting surgical video.
Growth Trajectory and Initiatives
Historical Growth: Intuitive Surgical has experienced significant growth in revenue, net income, and EPS over the past decade, driven by the increasing adoption of the da Vinci Surgical System.
Future Projections: Analysts expect Intuitive Surgical to continue to grow at a healthy pace in the coming years, driven by the expansion of surgical robotics into new markets and applications. Revenue and EPS are projected to increase at a double-digit rate.
Recent Initiatives: Recent initiatives include the launch of new surgical systems, such as da Vinci 5, expanding its presence in emerging markets, and investing in research and development to develop new technologies and applications.
Summary
Intuitive Surgical is a strong company with a dominant position in the surgical robotics market and an established brand. The company's recurring revenue stream from instruments and services provides stability. However, the company faces increasing competition, which can affect market share. Intuitive must continue to innovate and expand into new markets to maintain its competitive edge.
Similar Companies
JNJ
Johnson & Johnson
JNJ
Johnson & Johnson
MDT
Medtronic PLC
MDT
Medtronic PLC
ROBO
Robo Global® Robotics and Automation Index ETF
ROBO
Robo Global® Robotics and Automation Index ETF
XRAY
Dentsply Sirona Inc
XRAY
Dentsply Sirona Inc
Sources and Disclaimers
Data Sources:
- Company SEC Filings (10-K, 10-Q), Investor Presentations, Analyst Reports (e.g., from major investment banks like Goldman Sachs, Morgan Stanley), Market Research Reports (e.g., from Grand View Research, MarketsandMarkets), Company Website.
- Yahoo Finance
- Google Finance
Disclaimers:
The data and analysis provided are for informational purposes only and should not be considered investment advice. The information is based on available data and analyst estimates, which are subject to change. Investors should conduct their own research and consult with a financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Intuitive Surgical Inc
Exchange NASDAQ | Headquaters Sunnyvale, CA, United States | ||
IPO Launch date 2000-06-13 | CEO & Director Dr. Gary S. Guthart Ph.D. | ||
Sector Healthcare | Industry Medical Instruments & Supplies | Full time employees 15638 | Website https://www.intuitive.com |
Full time employees 15638 | Website https://www.intuitive.com | ||
Intuitive Surgical, Inc. develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables surgical procedures using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic endoluminal procedures enabling minimally invasive biopsies in the lung. It also provides a suite of stapling, energy, and core instrumentation for its multi-port da Vinci surgical systems; progressive learning pathways to support the use of its technology; infrastructure of service and support specialists, a complement of services to its customers, including installation, repair, maintenance, 24/7 technical support, and proactive system health monitoring; and integrated digital capabilities providing connected offerings, streamlining performance for hospitals with program-enhancing insights. The company sells its products through direct sales organizations, such as capital and clinical sales teams. Intuitive Surgical, Inc. was incorporated in 1995 and is headquartered in Sunnyvale, California.
Upturn is now on iOS and Android!
Experience Upturn on your mobile. Install it now!
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.